Tags |
|
|
Advice You - Change Management at Fast Moving Tech Companies Can Mean Disaster
Change management and fast-moving high-tech companies can be devast
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
ating for the efficiency and innovative spirit of the company. All
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
too often high-tech executives will find other work and leave the
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
ompany to go work for another corporation. Most sophisticated high
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
-tech companies understand this dynamic and therefore you strategie
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
such as stock options and golden handcuffs to keep their managers
ucts have become life saving products for the pharmaceutical companies who doesnt have many innovative molecules in their product pipeline and have been inc
and executives in place as long as possible.
Wall Street is also c
Wall Street is also c
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
oncerned with change management and fast-moving high-tech companies
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
and they realized that when there is corporate shakeup at the execu
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
tive level this could interfere with the company's productivity, ef
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
iciency and therefore profitability. Remember shareholders equity
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
in quarterly profits are the most important thing to Wall Street an
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
d if the company cannot beat the Street with increased per-share ea
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
nings then there will be held to pay in the stock price.
Of course
Of course
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
if there are executives or management teams, which are not working
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
out in the various departments or divisions of the high-tech compan
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
y there does need to be some shakeup of management otherwise it wil
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
l run amok. High-tech fast-moving companies must move fast in the m
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
rketplace with their products, as well as with their corporate mana
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
gement teams to keep the pace up. Please consider all this in 2006
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/14051/adviceyou-Change-Management-at-Fast-Moving-Tech-Companies-Can-Mean-Disaster.html">Change Management at Fast Moving Tech Companies Can Mean Disaster</a>
BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/14051/adviceyou-Change-Management-at-Fast-Moving-Tech-Companies-Can-Mean-Disaster.html]Change Management at Fast Moving Tech Companies Can Mean Disaster[/url]
Related Articles:
Credit Card Chargebacks: A Merchant's Most Difficult Challenge
How to Care for Cleaning Equipment
Survivor Winner, Yul Kwon - $1 Million Richer... But Still Searching for His True Calling
Bookmark it:
|